Slowing of brain atrophy with teriflunomide and delayed conversion to clinically definite MS.

ABSTRACT: Background:We explored the effect of teriflunomide on cortical gray matter (CGM) and whole brain (WB) atrophy in patients with clinically isolated syndrome (CIS) from the phase?III TOPIC study and assessed the relationship between atrophy and risk of conversion to clinically definite MS (CDMS). Methods:Patients (per McDonald 2005 criteria) were randomized 1:1:1 to placebo, teriflunomide 7?mg, or teriflunomide 14?mg for ?108?weeks (core study). In the extension, teriflunomide-treated patients maintained their original dose; placebo-treated patients were re-randomized 1:1 to teriflunomide 7?mg or 14?mg. Brain volume was assessed during years 1-2. Results:Teriflunomide 14?mg significantly slowed annualized CGM and WB atrophy versus placebo during years 1-2 [percent reduction: month 12, 61.4% (CGM; p?=?0.0359) and 28.6% (WB; p?=?0.0286); month 24, 40.2% (CGM; p?=?0.0416) and 43.0% (WB; p?

SUBMITTER: Zivadinov R 

PROVIDER: S-EPMC7672760 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature